Investigational drugs in thrombotic thrombocytopenic purpura

Expert Opinion on Investigational Drugs

Volumn 20, Issue 8, 2011, Pages 1087-1098

  Noris, Patrizia ^a   Balduini, Carlo L ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

ADAMTS13; ARC1997; Aspirin; Cyclosporine; Familial thrombotic thrombocytopenic purpura; N acetylcysteine; Nanobody ALX0681; Plasma exchange; Primary idiopathic thrombotic thrombocytopenic purpura; Recombinant ADAMTS13; Rituximab; Steroids; Von Willebrand factor

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALX 0681; ANTICOAGULANT AGENT; AUTOANTIBODY; CYCLOSPORIN; DIPYRIDAMOLE; EGAPTIVON PEGOL; FRESH FROZEN PLASMA; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; NANOBODY; PLACEBO; RECOMBINANT VON WILLEBRAND FACTOR CLEAVING PROTEINASE; RITUXIMAB; STEROID; TICLOPIDINE; UNCLASSIFIED DRUG; UNIPLAS; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANTIBODY PRODUCTION; DRUG MECHANISM; HUMAN; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; PROGNOSIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

EID: 79960350915     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.588599     Document Type: Review

References (85)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924;24:21-4
2. Tsai H-M. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010;91:1-19
3. Kiss JE. Thrombotic thrombocytopenic purpura: recognition and management. Int J Hematol 2010;91:36-45
4. Zipfel PF, Heinen S, Skerka C. Thrombotic microangiopathies: new insights and new challenges. Curr Opin Nephrol Hypertens 2010;19:372-8
5. Lotta LA, Garagiola I, Palla R, et al. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010;31:11-19
6. Noris M, Remuzzi G. Genetics and genetic testing in haemolytic syndrome/thrombotic thrombocytopenic purpura. Semin Nephrol 2010;30:395-408
7. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII, von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982;307:1432-5 (Pubitemid 13234018)
8. Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-44 (Pubitemid 26152267)
9. Furlan M, Robles R, Laemmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87:4223-34 (Pubitemid 26152266)
10. Kokame K, Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Semin Hematol 2004;41:34-40 (Pubitemid 38057783)
11. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600
12. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008;112:11-18
13. Coppo P, Wolf M, Veyradier A, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2006;132:66-74 (Pubitemid 43381572)
14. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADMTS13 antibody features (Ig isotype, titre, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood 2007;109:2815-22 (Pubitemid 46482076)
15. Zheng XL, Wu HM, Shang D, et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 2010;95:1555-62
16. Kremer Hovinga JA, Veseley SK, Terrel DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010;115:1500-11
17. Matsumoto M, Yagi H, Ishizashi H, et al. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Sem Hematol 2004;41:68-74 (Pubitemid 38057787)
18. Foley SR, Webert K, Arnold DM, et al. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney Int Suppl 2009;75:S55-8
19. Feys HB, Canciani MT, Peyvandi F, et al. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007;138:534-40 (Pubitemid 47063038)
20. Feys HB, Deckmyn H, Vanhoorelbeke K. ADAMTS13 in health and disease. Acta Haematol 2009;121:183-5
21. George JN. How I treat patients with thrombotic thrombocytopenic purpura. Blood 2010;116:4060-9
22. Lammle B, Kremer-Hovinga JA, George JN. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. Haematologica 2008;93:172-7 (Pubitemid 351397704)
23. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008;93:232-9 (Pubitemid 351397711)
24. Bukowski RM, King JW, Hewlett JS. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura. Blood 1977;50:413-17 (Pubitemid 8180423)
25. Byrnes JJ, Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med 1977;297:1386-9 (Pubitemid 8256298)
26. Byrnes JJ, Lian ECY. Recent therapeutic advances in thrombotic thrombocytopenic purpura. Semin Thromb Hemost 1979;5:199-215
27. Rock GA, Shumak KH, Buskard NA, et al.comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-7
28. Henon P. Treatment of thrombotic thrombocytopenic purpura. Results of a multicenter randomized clinical study. Presse Med 1991;20:1761-7
29. Rock G, Anderson D, Clark W, et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005;129:79-86 (Pubitemid 40524055)
30. Zeigler ZR, Shadduck RK, Gryn JF, et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001;16:19-22 (Pubitemid 32374499)
31. Owens MR, Sweeney JD, Tahhan RH, Fortkolt P. Influence of type of exchange fluid on survival in therapeutic apheresis for thrombotic thrombocytopenic purpura. J Clin Apher 1995;10:178-82 (Pubitemid 26019982)
32. Rock G, Shumak KH, Sutton DM, et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996;94:383-6 (Pubitemid 26248000)
33. Altuntas F, Aydogdu I, Kabukcu S, et al. Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci 2010;36:57-67 (Pubitemid 46341964)
34. Edel E, Al-Ali HK, Seeger S, et al. Efficacy and safety profile of solvent/detergent plasma in the treatment of acute thrombotic thrombocytopenic purpura: a single-center experience. Transfus Med Hemother 2010;37:13-19
35. Alvarez-Larran A, Del Rio J, Ramirez C, et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004;86:246-51 (Pubitemid 38902095)
36. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006;46:1693-704 (Pubitemid 44435721)
37. De la Rubia J, Arriaga F, Linares D, et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001;114:721-3 (Pubitemid 32953658)
38. Bramlage CP, Schroder K, Bramlage P, et al. Predictors of complications in therapeutic plasma exchange. J Clin Apher 2009;24:225-31
39. Scully M, Longair I, Flynn M, et al. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007;93:154-8 (Pubitemid 47228496)
40. Mc Carthy LJ, Dlott JS, Orazi A, et al. Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow. Ther Apher Dial 2004;8:80-6 (Pubitemid 38796936)
41. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica 1997;82:429-35
42. Bennett CL, Weinberg PD, Rozemberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998;128:541-4 (Pubitemid 28177661)
43. Rosove MH, Ho WG, Goldfinger D. Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura. Ann Intern Med 1982;96:27-33 (Pubitemid 12205511)
44. Gilbert JC, De Feo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation on anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007;116:2678-86 (Pubitemid 350291240)
45. Mayr FB, Knobl P, Jilma B, et al. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion 2010;50:1079-87
46. Knobl P, Jilma B, Gilbert JC, et al. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion 2009;49:2181-5
47. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, et al. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011;105:545-52
48. Cataland SR, Peyvandi F, Mannucci PM, et al. A randomized, double-bind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Blood 2010;116:abstract 726
49. Van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications. Curr Opin Investig Drugs 2009;10:1212-24
50. Bartunek J, Barbato E, Vercruysse K, et al. Safety and efficacy of anti-von Willebrand Factor Nanobody- ALX-0081 in stable angina patients undergoing percutaneous coronary intervention. Circulation 2010;122:A15084 effect of platelet aggregation
51. Balduini CL, Gugliotta L, Luppi M, et al. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 2010;89:591-6
52. Bell WR, Braine HG, Ness PM, Kicker TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991;325:398-403
53. Rojnuckarin P, Watanaboonyongcharoen P, Akkawat B, Intragumtornchai T. The role of pulse dexamethasone in acquired idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2007;4:1148-50
54. Toyoshige M, Zaitsu Y, Okafuji K, et al. Successful treatment of thrombotic thrombocytopenic purpura with high-dose corticosteroids. Am J Hematol 1992;41:69
55. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to four-dose treatment program. J Clin Oncol 1998;16:2825-33 (Pubitemid 28363048)
56. Stasi R, Stipa E, Forte V, et al. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002;99:3872-3 (Pubitemid 34534570)
57. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004;103:4424-8 (Pubitemid 38745966)
58. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with choric immune thrombocytopenic purpura. Br J Haematol 2004;125:232-9 (Pubitemid 38534976)
59. Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS13. Br J Haematol 2007;136:451-61 (Pubitemid 46046304)
60. McDonald V, Liesner R, Grainger J, et al. Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS13 assay. Blood Coagul Fibrinolysis 2010;21:254-0
61. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005;106:1932-7 (Pubitemid 41291703)
62. Caramazza D, Quintini G, Abbene I, et al. Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura - haemolytic uraemic syndrome. Blood Transfus 2010;8:203-10
63. De la Rubia J, Moscardo F, Gomez MJ, et al. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfus Apher Sci 2010;43:299-303
64. Bresin E, Gastoldi S, Daina E, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 2009;101:233-8
65. Heidel F, Lipka DB, von Auer C, et al. Addition of rituximab therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 2007;97:228-33 (Pubitemid 46592142)
66. Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol 2009;84:418-21
67. Lombardi AM, de Marinis GB, Scandellari R, et al. Clinical biological remission induced by rituximab in acute refractory chronic relapsing TTP. Thromb Res 2010;126:e154-6
68. Chemnitz JM, Uener J, Hallek M, Scheid C. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol 2010;89:1029-33
69. McDonald V, Manns K, Mackie IJ, et al. Rituximab pharmacokinetics during the treatment of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010;8:1201-8
70. Elliott MA, Heit JA, Pruthi RK, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Eur J Haematol 2009;83:365-72
71. Scully M, Cavenagh JD, Hunt B, et al. A phase II study to assess the safety, efficacy and tolerability of rituximab (Mabthera) in combination with plasma-exchange in patients with acute thrombotic thrombocytopenic purpura (TTP). Blood 2010;116:A3699
72. Kiedorf H, Maurin N, Heintz B. Cyclosporine for thrombotic thrombocytopenic purpura. Ann Intern Med 1993;118:987-8
73. Cataland SR, Jin M, Ferketich AK, et al. An evaluation of ciclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2006;136:146-9
74. Cataland SR, Jin M, Lin S, et al. Ciclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol 2007;139:486-93 (Pubitemid 47512185)
75. Cataland SR, Ming J, Lin S, et al. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol 2008;83:911-15
76. Graham RM. Cyclosporine: mechanism of action and toxicity. Cleve Clin J Med 1994;61:308-13
77. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura hemolytic uremic syndrome. Curr Opin Hematol 2001;8:286-93 (Pubitemid 32826498)
78. Chen J, Reheman A, Gushiken FC, et al. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 2011;121:593-603
79. Sandilands EA, Bateman DN. Adverse reactions associated with acetylcysteine. Clin Toxicol (Phila) 2009;47:81-8
80. Knudsen TT, Thorsen S, Jensen SA, Dalhoff K. Effect of intravenous N-acetylcysteine infusion on haemostatic parameters in healthy subjects. Gut 2005;54:515-21 (Pubitemid 40395504)
81. Wijeysundera DN, Karkouti K, Rao V, et al. N-acetylcysteine is associated with increased blood loss and blood product utilization during cardiac surgery. Crit Care Med 2009;37:1929-34
82. Plaimauer B, Zimmermann K, Volkel D, et al. Cloning, expression and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002;100:3626-32 (Pubitemid 35303932)
83. Antoine G, Zimmermann K, Plaimauer B, et al. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol 2003;120:821-4 (Pubitemid 36315105)
84. Plaimauer B, Kremer Hovinga JA, Juno C, et al. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving protease activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 2011;published online 5 February 2011; doi: 10.1111/j.1538- 7836.2011.04224.x
85. Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on Thrombopoiesis, I: a factor in normal human plasma required for platelet production: chronic thrombocytopenia due to its deficiency. Blood 1960;16:1350-2